Treat only what needs treating, spare the rest
Na interseção entre ciência e dignidade humana, o Brasil deu um passo significativo ao autorizar duas terapias focais para o câncer de próstata localizado — o HIFU e a crioablação. O Conselho Federal de Medicina reconheceu, em 27 de maio, que tratar apenas o tumor, e não o órgão inteiro, pode preservar aquilo que a doença e seus tratamentos tradicionais tantas vezes roubam: a continência, a sexualidade, a inteireza do homem após a cura. É um movimento que reflete uma mudança mais profunda na oncologia moderna — a compreensão de que eficácia e qualidade de vida não precisam ser adversárias.
- Décadas de tratamento padrão deixaram incontáveis homens curados do câncer, mas às custas de disfunção erétil, incontinência e perda da ejaculação — efeitos colaterais que o campo médico finalmente se propõe a enfrentar com mais precisão.
- O CFM autorizou o HIFU e a crioablação para tumores localizados de risco intermediário-favorável, abrindo uma nova frente terapêutica que existia na prática internacional, mas aguardava reconhecimento oficial no Brasil.
- As duas técnicas atuam por mecanismos opostos — calor extremo versus frio extremo — mas compartilham o mesmo princípio: destruir o tumor com margem de segurança sem tocar no tecido saudável ao redor.
- Com taxas de efeitos adversos urológicos e sexuais em torno de 5%, contra índices muito mais elevados nas abordagens tradicionais, a diferença para um homem de 50 ou 60 anos é profunda e concreta.
- Avanços em imagem e na compreensão do comportamento tumoral tornaram possível identificar quais pacientes realmente precisam de tratamento radical — e quais podem ser poupados dele.
O Conselho Federal de Medicina autorizou, em 27 de maio, o uso do HIFU e da crioablação no tratamento do câncer de próstata localizado de risco intermediário-favorável. A resolução representa uma virada: em vez de remover ou irradiar toda a glândula, os médicos podem agora tratar apenas a região do tumor.
Para os pacientes, a diferença é enorme. A cirurgia tradicional e a radioterapia carregam riscos reais de incontinência urinária, disfunção erétil e perda da ejaculação. As novas terapias focais reduzem esses efeitos adversos a cerca de 5% dos casos, segundo o urologista Stenio Zequi, do A.C. Camargo Cancer Center. Para um homem em plena vida ativa, essa distinção não é estatística — é existencial.
O HIFU aquece o tecido tumoral a aproximadamente 90 graus Celsius com ondas de ultrassom de alta intensidade. A crioablação faz o caminho inverso, congelando o tumor por meio de agulhas posicionadas com precisão. Ambos os procedimentos são guiados por imagem, realizados sob anestesia leve e permitem alta no mesmo dia.
A autorização também reflete uma mudança conceitual mais ampla: nem todo câncer de próstata se comporta da mesma forma. Alguns crescem lentamente e podem ser monitorados; outros exigem intervenção imediata. A melhora nas tecnologias de imagem e no entendimento do comportamento tumoral permite hoje identificar com mais precisão qual caminho cada paciente deve seguir — e, em muitos casos, esse caminho pode ser menos invasivo do que se supunha necessário.
Brazil's medical establishment has just cleared the way for two new approaches to treating prostate cancer, and the shift signals something larger than a pair of new procedures. On Wednesday, May 27th, the Federal Medical Council issued a resolution authorizing high-intensity focused ultrasound (HIFU) and cryoablation for men with localized prostate tumors of intermediate-favorable risk. Both techniques represent a departure from the standard playbook that has dominated for decades: instead of removing the entire prostate or bombarding the whole gland with radiation, doctors can now target only the tumor itself.
For men facing a prostate cancer diagnosis, this matters enormously. Traditional surgery removes the entire prostate, which can leave patients dealing with urinary incontinence, erectile dysfunction, and loss of ejaculation. Radiation therapy, even modern versions, carries similar risks—sexual dysfunction is common, and some protocols combine radiation with hormone therapy that further dampens libido. The new focal therapies promise something different. According to Stenio Zequi, a urologist and director of the Urological Tumor Reference Center at A.C. Camargo Cancer Center, these approaches produce adverse urinary and sexual effects in roughly 5 percent of cases, compared to much higher rates with traditional treatments.
The authorization applies specifically to men whose cancer is confined to one region of the prostate and shows intermediate-favorable risk characteristics. It also covers certain cases where patients have already undergone radiation or have low-risk disease. What makes this possible is a fundamental shift in how doctors understand prostate cancer itself. Not all prostate cancers behave the same way. Some grow so slowly they can be monitored for years without intervention. Others demand aggressive action. The majority fall somewhere in between—contained to one area, curable with the right approach, but not so aggressive that they require the sledgehammer of whole-gland treatment.
Advances in imaging technology and a deeper understanding of tumor behavior have made this precision possible. Doctors can now identify with much greater accuracy which patients truly need radical treatment and which can be managed more conservatively. That knowledge has gradually reshaped how the field thinks about the disease.
The two approved techniques work through opposite mechanisms but share the same goal: destroy the tumor while preserving healthy tissue. HIFU uses high-intensity ultrasound waves to heat the target tissue to about 90 degrees Celsius, killing cancer cells while leaving surrounding structures intact. Cryoablation does the reverse, using needles positioned in the prostate to freeze tumor tissue to extremely low temperatures. Both procedures are guided by imaging and include a safety margin around the lesion. Both are typically performed under light anesthesia, take relatively little time, and often allow patients to go home the same day.
Zequi emphasizes that the real appeal lies in what these treatments spare patients. Even with robotic surgery and modern radiation techniques, the risk of urinary and sexual complications remains real and significant. Focal therapies dramatically reduce that risk. For a man in his 50s or 60s, the difference between a 5 percent chance of erectile dysfunction and a much higher probability is not a minor distinction—it touches on fundamental aspects of quality of life and identity.
This approval reflects a broader movement in oncology toward treating only what needs to be treated. The goal is not to abandon efficacy but to achieve it with the smallest possible footprint. For prostate cancer patients in Brazil, it means the conversation with their doctor can now include options that were not available before—treatments that take the disease seriously without necessarily taking a toll on the life they want to live after treatment ends.
Notable Quotes
Even with robotic surgery and modern radiation techniques, the risk of urinary and sexual complications remains real and significant— Stenio Zequi, urologist and director of the Urological Tumor Reference Center at A.C. Camargo Cancer Center
The Hearth Conversation Another angle on the story
Why does it matter that these are focal therapies rather than whole-gland treatments?
Because the prostate isn't just a tumor—it's also tissue involved in sexual function and urinary control. Remove or irradiate the whole thing, and you're almost guaranteed to damage those systems. Focal therapy says: we know exactly where the cancer is, so we treat only that spot.
But doesn't that risk leaving cancer behind?
Not for the right patients. That's the key. These techniques are approved only for men whose cancer is localized to one area and shows intermediate-favorable risk. If the cancer is aggressive or spread, you still need traditional treatment. The imaging advances now let doctors distinguish between those cases.
What changed to make this possible?
Better imaging and years of data on how different prostate cancers actually behave. Doctors realized that many men were getting treated far more aggressively than their disease warranted. Some cancers grow so slowly they barely matter. Others need the full arsenal. Most fall in between.
So this is really about precision—treating the right patient with the right intensity?
Exactly. It's the opposite of one-size-fits-all. A 55-year-old with intermediate-risk cancer in one spot of his prostate now has a real option to preserve sexual function and continence. That's not a small thing.
What's the recovery like compared to surgery?
Much lighter. Light anesthesia, same-day discharge usually. You're not cutting out an organ or irradiating a whole gland. The procedure is targeted and brief.
Does this mean traditional surgery is becoming obsolete?
No. For aggressive cancers or disease that's spread, you still need it. But for a significant group of patients—maybe the majority—this opens a door that didn't exist before.